Tower Research Capital (TRC)’s Lexeo Therapeutics LXEO Stock Holding History
Bought
Maintained
Sold
Other funds holding LXEO
Tower Research Capital (TRC)'s LXEO Position: Q3 2026 in Review
Tower Research Capital (TRC) increased its Lexeo Therapeutics (LXEO) stake by 97% in Q3 2026, buying an estimated $23K and bringing the position to 10,315 shares worth $34.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3443.
Tower Research Capital (TRC) first reported a position in LXEO in Q4 2023 and has held it in 12 quarters since. The position peaked at $54.4K in Q1 2026. 153 funds tracked by Wall St. Rank hold LXEO as of Q3 2026.
- Tower Research Capital (TRC) held 10,315 shares of Lexeo Therapeutics worth $34.9K as of Q3 2026.
- Tower Research Capital (TRC) bought 5,078 Lexeo Therapeutics shares in Q3 2026, an estimated $23K.
- Lexeo Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #3443 holding.
- Tower Research Capital (TRC) first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 12 quarters since.
- Tower Research Capital (TRC)'s Lexeo Therapeutics position peaked at $54.4K in Q1 2026.
- 153 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.